Target intelligence / Profile preview

Family with sequence similarity 3 member C (FAM3C)

Target
FAM3C
Molecular classification
Secreted protein, Cytokine-like protein, Other
01

Overview

Family with sequence similarity 3 member C (FAM3C) is a secreted, cytokine-like protein involved in regulating mechanisms such as epithelial-mesenchymal transition (EMT), cell proliferation, and tissue development[1][4][5]. It is highly conserved across species and broadly expressed, including notable expression in secretory epithelia and the nervous system. FAM3C is notably upregulated in several cancers, where it promotes metastasis and is considered essential for tumor formation and progression in epithelial tissues[6]. Altered expression is also associated with neurodegenerative conditions, particularly Alzheimer’s disease, where decreased levels correlate with disease onset and may serve as a diagnostic biomarker. Structurally, FAM3C does not resemble classical interleukins, despite its functional analogy and alternative name as “Interleukin-like EMT inducer (ILEI)”[6]. Its exact physiological and pathological mechanisms remain under investigation, with potential roles as a therapeutic target in oncology and neurology[1][2][4].

Other names
ILEIGS3786GS3876Protein FAM3CInterleukin-like EMT inducerInterleukin-like epithelial-mesenchymal transition inducerPredicted osteoblast proteinFAM3 metabolism regulating signaling molecule Cfamily with sequence similarity 3 member C
02

Mechanism of action

Not established for specific drugs; therapeutics under investigation include modulation of FAM3C expression or function (gene therapy, protein inhibitors/agonists, antibodies)

03

Biological functions

Epithelial-mesenchymal transition (EMT)Regulation of signaling receptor activityRetinal laminar formationCell proliferation and differentiationMulticellular organism developmentNegative regulation of receptor signaling
04

Disease associations

Cancer (tumor formation, metastasis in epithelial cancers)Neurodegenerative disease (notably Alzheimer’s disease)Hearing loss (linked to DFNB17 locus)
05

Safety considerations

Not established; theoretical concerns may include off-target effects due to FAM3C’s broad tissue expression and diverse roles in development, cancer, and brain function
06

Interacting drugs

None reported in primary sources; drug development is in discovery/preclinical exploration stages
07

Biomarkers

FAM3C protein levels as a biomarker for Alzheimer's disease (together with saposin D)Upregulation as a prognostic marker in some cancers (e.g., breast, colon)

Beyond the preview

Go deeper on Family with sequence similarity 3 member C (FAM3C).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Family with sequence similarity 3 member C (FAM3C).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call